InVentiv Health to buy SDI audits from IMS

Share this article:

Privately held inVentiv Health will acquire two of SDI Health's audit businesses worth under $15 million, according to company statements. IMS Health agreed to divest the units when regulators approved its purchase of SDI last year.


The promotional and medical audit businesses will be incorporated into the offerings of inVentiv Health's Campbell Alliance biopharma management consulting unit.


"This is an important step in boosting inVentiv's capabilities in market research and analytics," said Paul Meister, CEO, inVentiv Health, in a statement.


Campbell Alliance already has a market research and analytics group offering a range of longitudinal de-identified patient and prescription data and analytics services. The firm will combine the acquired business with the group, which also provides custom quantitative research, qualitative market research, and key opinion leader identification and mapping.


The deal follows IMS Health's acquisition of SDI Health, formally approved October 31, after which its parent company, Healthcare Technology Holdings, moved forward to divest the two SDI product lines, as per a settlement order proposed by the Federal Trade Commission to preserve competition.


In the settlement order, the FTC had required IMS to sell the two businesses to a buyer within three months of the completion of the deal, or Jan. 31, 2012.


Financial terms were not disclosed, but in a statement about yesterday's sale to inVentiv, IMS revealed that, under the two businesses it divested are a number of different data products, 11 to be exact. These products, which needed to be sold off to satisfy the FTC requirements, represent less than $15 million, or about 10% of SDI's 2011 revenue.

IMS will continue to market its existing medical and promotional services worldwide, the firm said, including the company's National Disease and Therapeutic Index (NDTI) and Integrated Promotional Services (IPS) offerings in the US.

"With the acquisition of SDI, IMS continues to build more innovative and comprehensive capabilities in the patient and payer spaces, consistent with the company's strategy to significantly expand its business in healthcare information, technology and services," IMS concluded.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.